Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy elicits durable antitumor responses in patients with many types of cancer. Genomic mutations may be used to predict the clinical benefits of ICI therapy. NOTCH homolog-4 (NOTCH4) is frequently mutated in several cancer types, but its role in immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Junyu, Wang, Dongxu, Yang, Xu, Wang, Anqiang, Lin, Yu, Zheng, Mingjun, Zhang, Haohai, Sang, Xinting, Wang, Hanping, Hu, Ke, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293505/
https://www.ncbi.nlm.nih.gov/pubmed/34284787
http://dx.doi.org/10.1186/s12916-021-02031-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8293505/
https://www.ncbi.nlm.nih.gov/pubmed/34284787
http://dx.doi.org/10.1186/s12916-021-02031-3

Ejemplares similares